A decade after the suit was filed claiming pharmaceutical companies Mylan and Teva conspired to stall generic narcolepsy medication Provigil, a settlement has been reached. Plaintiffs in the suit argued that the companies engaged in “unlawful reverse payment agreements,” causing Provigil overpayment and boosting their own sales. A spokesperson for Mylan said of the settlement, “Nothing in the settlement agreement constitutes an admission of wrongdoing … the proposed settlement is in the best interests of the company and is an important step in moving forward.” This settlement is the latest in a string of legal issues for Mylan, including an EpiPen pricing controversy and extensive layoffs. Read the full article here.
